A biochemical detection device with a controlled reaction incubation time includes a substrate; a probe disposed on the substrate; a dissolvable material layer disposed on the substrate, wherein the dissolvable material layer has a first opening defined therein, wherein the probe is received in the first opening; an absorbing material layer disposed on the dissolvable material layer and having a second opening defined therein, wherein the first opening communicates with the second opening and is smaller than the second opening; and a non-dissolvable material layer disposed on an inner face of the second opening of the absorbing material layer and on an exposed top face of the dissolvable material layer.

A method for diagnosing tuberculosis of the present invention can improve the reactivity of tuberculous antigens and detection antibodies by increasing free tuberculous antigens in a sample through a pretreatment step in which the sample of a subject is treated with an acidic material such that the antigens are dissociated from tuberculous antigen complexes, thereby enabling a point-of-care test for tuberculosis and being immediately utilizable as a fast and simple detection method for a point-of-care test.

The present invention includes an in-situ method, comprising a) determining a molecule selected from the group consisting of cell surface molecules and extracellular matrix molecules in a two- or three-dimensional cell culture system comprising living cells and cell culture medium, comprising the steps of i) providing an analyte probe consisting of a detection element, which binds the molecule, and one or more identification elements; ii) binding of the analyte probe to the molecule in the cell culture system, wherein the growth ability of the contained living cells is not substantially impaired by this step; iii) optionally removing unbound analyte probes; iv) releasing the analyte probe; v) transferring the analyte probe into a container which differs from the cell culture system; vi) detecting the identification element(s); and b) continuing the cell cultivation in the cell culture system.

The present disclosure is directed to antibody-linked immuno-sedimentation agent, the antibody being linked to a sedimentation agent by a non-antigen binding region of the antibody, and a method of isolating a target from a sample using the antibody-linked immuno-sedimentation agent. The methods involve forming a mixture including a sample with an antibody linked immuno-sedimentation agent and red blood cells under conditions sufficient to form red blood cell rouleaux and allow antibody-antigen binding.

This invention relates to imaging, such as by expansion microscopy, labelling, and analyzing biological samples, such as cells and tissues, as well as reagents and kits for doing so.

The present invention provides a detection method for a monoclonal antibody in a sample, comprising: (a) a step of capturing the monoclonal antibody in the sample and immobilizing the monoclonal antibody in pores of a porous body; (b) a step of bringing the porous body in which the monoclonal antibody is immobilized with nanoparticles on which protease is immobilized to conduct selective protease digestion of the monoclonal antibody; (c) a step of detecting, by a liquid chromatography mass spectrometry (LC-MS), peptide fragments obtained by the selective protease digestion; and (a) a step of conducting a reduction reaction under an acidic condition after the step (a). By the present invention, further applicability of the detection method for the monoclonal antibodies using mass spectrometry is expected.

According to one embodiment, a method of detecting or quantifying a detection target in a specimen includes: irradiating a reaction mixture containing composite particles and the specimen with light to promote binding between the composite particles and the detection target; and performing measurement on the reaction mixture irradiated with the light to detect or quantify the detection target. The composite particles each include a carrier particle including two or more regions having different physical properties on a surface, and an affinity substance carried on the carrier particle and having affinity to the detection target. The light can be absorbed by at least one of the two or more regions.

A method for detecting a presence and/or a concentration of a target substance in a reagent solution using enzyme-linked immunosorbent assay (ELISA) includes binding the target substance directly or indirectly to an electrode, and binding a detection agent directly or indirectly to the bound target substance. The method further includes modulating a pH of only a portion of the reagent solution in which the bound target substance and the bound detection agent are located using the electrode, the modulated pH of the portion of the reagent solution causing the bound detection agent to undergo a change, and detecting the change in the bound detection agent. The detected change corresponds to the presence of the target substance in the reagent solution and/or the concentration of the target substance in the reagent solution.

The disclosure provides a reagent for extracting immunosuppressant drugs from whole blood sample for immunoassay. The extraction reagent comprises protein denaturant, proteolytic enzyme, surfactant and pH buffer. The disclosure also provides a method and an immunoassay kit for detection of the immunosuppressant concentration in a whole blood sample using the extraction reagent. The extraction reagent of the present disclosure doesn't need the use of organic solvent as that in the traditional extraction method, therefore the adverse effects of the organic solvent on the antibody activity in a detection system and the other relative defects associated to its use are obviated. The drug extraction process of the present disclosure doesn't need centrifugation, the processed sample can be directly applied for immunoassay. The operation for drug extraction by the present disclosure is simple, and the detection result based on this extraction method is accurate.

The present disclosure relates generally to nanoparticle aggregates and to methods for preparing nanoparticle aggregates in a controlled manner The nanoparticle aggregates are useful in a variety of applications including detection and quantitation assays. In one illustrative example, the nanoparticle aggregates are particularly useful in medical diagnostic applications.